Bausch + Lomb Micronizes Lutein, Zeaxanthin In PreserVision OCUSorb
Analysts: No Small Impact On B+L Credit Rating From Bausch Health Continued Ownership
Executive Summary
PreserVision AREDS 2 mini-softgel has proprietary OCUSorb formulation with micronized ingredients in a medium-chain triglyceride oil. More than line extensions, though, are needed for B+L to shed influence from Bausch Health’s credit rating.
You may also be interested in...
US Q4 Consumer Health Earnings Preview: Will Demand Or Shortage Have More Impact?
Demand for OTC pain relievers and cough/cold products jumped prior to October-December and remained high during quarter due to consumer concern not only about flu but also RSV and additional COVID-19 mutation. US and Canadian firms marketing OTC drugs and supplements also will be offering additional signals on planned spinoffs of consumer health businesses.
Bausch + Lomb CEO Leaving 10 Weeks Following IPO, Month After Icahn Gains Two Board Seats
Joseph Papa steps down as chair and will remain at helm and on board until successor appointed. Guggenheim analysts reported representatives on B+L board for activist investor Carl Icahn appointed a month ago likely led to Papa’s exit.
Bausch + Lomb Separates From Bausch Health After Delivering Its Only First-Quarter Sales Growth
Bausch Health closed Bausch + Lomb IPO offering 10% of shares instead of 20% planned. Bausch + Lomb’s $889m Q1 revenue up 1% while other Bausch Health divisions slumped.